Kisspeptin-10 is a research peptide studied in academic settings. It is not an approved therapy. This page describes investigational and hypothesized effects, not established treatments.
The short answer
Kisspeptin-10 is unusual among research peptides in that it has genuine human data — controlled infusion studies at named doses with measured hormone outputs. What those studies establish is that it works on the reproductive axis exactly as its biology predicts: it acts on the KISS1 receptor to stimulate GnRH release, which drives LH and FSH from the pituitary. It is the minimal kisspeptin sequence retaining full intrinsic bioactivity.
What they do not establish is a therapy. The published work characterises physiology and probes axis function; it does not demonstrate a clinical benefit for fertility, libido, or hormone optimisation, and no kisspeptin product is approved anywhere.
What happens in men
The dose-response has been mapped. In healthy men given intravenous bolus doses of 0.01 to 3.0 µg/kg, kisspeptin-10 produced a rapid, dose-dependent rise in serum LH, with maximal stimulation at 1 µg/kg — LH rising from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at 30 minutes (n=6) (PMID 21632807).
Two findings from that study matter more than the headline number:
- The response is not monotonic. The 3 µg/kg dose elicited a reduced response compared with 1 µg/kg. More was less.
- Continuous infusion changes the pulse architecture. Infusing at 1.5 µg/kg·h raised mean LH from 5.2 to 14.1 IU/L, increased LH pulse frequency from 0.7 to 1.0 pulses per hour, and increased secretory burst mass from 3.9 to 12.8 IU/L. At a higher infusion rate of 4 µg/kg·h over 22.5 hours, LH rose from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L — but LH pulses were obscured entirely at that rate of secretion.
That testosterone figure is the one most often quoted out of context. It is a roughly 45% rise measured during a 22.5-hour intravenous infusion in a research unit — not a result from an injection regimen, and not sustained beyond the infusion.
What happens in women — and what does not
The response is sexually dimorphic and, in women, cycle-phase dependent. In a study comparing intravenous kisspeptin-10 in healthy men and women, men showed elevated LH at doses as low as 0.3 nmol/kg and elevated FSH from 1.0 nmol/kg. Women in the follicular phase showed no alteration in serum gonadotropins at the doses tested, while women in the preovulatory phase did respond (PMID 21976724).
This is a useful corrective to any framing of kisspeptin as a general hormone-boosting agent. The same dose in the same species produced a hormonal response or no response at all depending on sex and on where in the menstrual cycle it was given. The axis's readiness, not the peptide, determined the outcome.
The IVF trigger idea
The most developed clinical hypothesis is using kisspeptin to trigger oocyte maturation during IVF. The rationale is safety rather than efficacy: IVF uses supraphysiological stimulation, and the choice of trigger — hCG or a GnRH agonist — affects both luteal-phase hormone dynamics and the risk of ovarian hyperstimulation syndrome. Because kisspeptin acts upstream at GnRH neurons and is requisite for the physiological ovulatory LH surge, a kisspeptin trigger would evoke the body's own surge rather than substituting a long-acting analogue for it (PMID 36147569).
This remains a research direction under investigation, not an approved or standard-of-care option.
The brain-imaging strand
A separate line of work looked above the hypothalamus. In a study of 29 healthy heterosexual young men comparing kisspeptin against vehicle with functional neuroimaging plus hormonal and psychometric measures, kisspeptin enhanced limbic brain activity specifically in response to sexual and couple-bonding stimuli. The enhancement correlated with psychometric measures of reward, drive, mood, and sexual aversion, and kisspeptin administration attenuated negative mood (PMID 28112678).
The finding is genuinely novel — it suggests kisspeptin integrates sexual and emotional processing with the hormonal reproductive axis. It is also a single-session imaging study in 29 men, measuring brain activation and questionnaire scores rather than any behavioural or clinical outcome.
What none of this establishes
Every result above comes from intravenous administration under controlled conditions, in small samples, with effects lasting as long as the infusion. Kisspeptin-10 has a short half-life, no approved indication, and no dosing standard for use outside a protocol. The evidence describes a well-behaved research tool for interrogating the hypothalamic-pituitary-gonadal axis — which is a real contribution, and a different claim from "it works." Safety considerations, including what happens under sustained exposure, are on the side-effects page.